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Summary: 
First-line anti-tuberculosis drugs achieve higher concentrations in the lung than in plasma in 
patients on treatment. Despite standard weight-based dosing, rifampicin concentrations are 
particularly low in plasma, epithelial lining fluid and alveolar cells. Dose refinement may be 
required.  
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Abstract 
BACKGROUND: Further work is required to understand the intrapulmonary 
pharmacokinetics of first-line anti-tuberculosis drugs. This study aimed to describe the 
plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and 
ethambutol, and explore relationships with clinical treatment outcomes in patients with 
pulmonary tuberculosis. 
 
METHODS: Malawian adults with a first presentation of microbiologically-conf rmed 
pulmonary tuberculosis received standard 6-month first-line therapy. Plasma and 
intrapulmonary samples were collected 8 and 16 weeks into treatment and drug 
concentrations measured in plasma, lung/airway epithelial lining fluid, and alveolar cells. 
Population pharmacokinetic modelling generated estimates of drug exposure (Cmax and AUC) 
from individual-level post-hoc Bayesian estimates of plasma and intrapulmonary 
pharmacokinetics.  
 
RESULTS: One-hundred-and-fifty-seven patients (58% HIV co-infected) participated. Despite 
standard weight-based dosing, peak plasma concentrations of first-line drugs were below 
therapeutic drug monitoring targets. Rifampicin concentrations were low in all three 
compartments. Isoniazid, pyrazinamide, and ethambutol achieved higher concentrations in 
epithelial lining fluid and alveolar cells than plasma. Isoniazid and pyrazinamide 
concentrations were 14.6 (95% CI: 11.2-18.0) and 49.8-fold (95% CI: 34.2-65.3) higher in 
lining fluid than plasma respectively. Ethambutol concentrations were highest in alveolar 
cells (alveolar cells:plasma ratio 15.0, 95% CI 11.4-18.6). Plasma or intrapulmonary 
pharmacokinetics did not predict clinical treatment response. 
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CONCLUSIONS: We report differential drug concentrations between plasma and the lung. 
While plasma concentrations were below therapeutic monitoring targets, accumulation of 
drugs at the site of disease may explain the success of the first-line regimen. The low 
rifampicin concentrations observed in all compartments lend strong support for ongoing 
clinical trials of high-dose rifampicin regimens.  
 
Keywords: tuberculosis, pulmonary; pharmacokinetics; pharmacodynamics; antibiotics, 
antitubercular 
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Introduction 
Whilst effective antibiotics for tuberculosis (TB) have been widely available for several 
decades, cure rates in high burden countries remain variable [1]. Revisiting the 
pharmacokinetics-pharmacodynamics of first-line agents, in patients with active pulmonary 
disease, may identify opportunities to optimise or abbreviate anti-TB treatment. 
 
Plasma pharmacokinetic indices for first-line anti-TB drugs vary by up to 10-fold between 
individuals [2–5] and their relationship with treatment response has varied across studies 
using differing methodologies [6–10]. We hypothesised that intrapulmonary 
pharmacokinetics will differ between individuals and may explain drug exposure-response 
relationships. Novel work using lung explants and spatial mass spectrometry has 
demonstrated gradients of both drug exposure and Mycobacterium tuberculosis drug-
sensitivity in granulomas and cavities [11,12], but can only be performed in a small subset of 
patients with advanced disease.  
 
In this study, drug concentrations in lung epithelial lining fluid and alveolar cells were used 
to assess intrapulmonary penetration, as expressed by epithelial lining fluid:plasma or 
alveolar cells:plasma concentration ratios. These ratios, described for a wide range of 
antimicrobials [13,14], may inform an assessment of whether penetration is sufficient when 
related to the minimum inhibitory concentration for the infecting organism [15,16]. Few 
existing healthy volunteer-based data suggest extensive variability in the pulmonary 
penetration of first-line anti-TB drugs, with potentially sub-therapeutic concentrations of 
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rifampicin and isoniazid in epithelial lining fluid in a proportion of subjects [17–22]. These 
studies have limitations, however, as no patients with TB participated, drugs were given 
individually rather than in clinically relevant combinations, and sampling was limited to 
single fixed time-points.  
 
To address these limitations, we used bronchoalveolar lavage coupled with population 
pharmacokinetic modelling to assess site of disease pharmacokinetics in a cohort of adult 
pulmonary TB patients receiving first-line anti-TB treatment. 
Methods 
Study design 
This was a prospective, single-centre, pharmacokinetic-pharmacodynamic study. 
Participants were sequentially assigned to two study arms – a plasma arm and an 
intrapulmonary arm - at a 2:1 allocation ratio. 
 
The primary objective was to describe the pharmacokinetics (area-under-the-concentration-
time-curve [AUC] and peak concentration [Cmax]) of rifampicin, isoniazid, pyrazinamide, and 
ethambutol in plasma, lung epithelial lining fluid, and alveolar cells. The secondary objective 
was to relate the pharmacokinetic indices to clinical treatment response. 
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Study participants 
The study was conducted at Queen Elizabeth Central Hospital in Blantyre, Malawi, between 
January 2016 and October 2018. Patients registering for first-line treatment for TB at the 
hospital, or at health centres in urban Blantyre, were screened. Adults aged 16-65 years 
with sputum smear- or Xpert MTB/RIF-positive pulmonary TB were eligible while those with 
absolute or relative contraindications to research bronchoscopy were excluded [23] 
(Supplementary Materials). Baseline chest radiographs were scored for severity of disease 
[24]. 
 
Participants received daily fixed-dose combination t blets according to a WHO-approved 
weight-adjusted regimen and national guidelines [25]. All participants had HIV antibody 
tests and those who tested positive received antiretroviral therapy [26]. Participants were 
followed up for 18 months. Adherence was monitored by direct questioning and pill counts.   
 
Pharmacokinetic sampling 
Pharmacokinetic sampling was completed at 7-8 and 15-16 weeks into TB treatment. All 
participants were observed to take their anti-TB treatment after an overnight fast. Those in 
the plasma arm had blood samples collected at 1 and 3 or 2 and 4 hours post-dose. Those in 
the intrapulmonary arm had blood samples collected pre-dose, and at 0.5, 1, 3, 5 or 2, 4, 6, 
8 hours post-dose.  
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Participants in the intrapulmonary arm had a research bronchoscopy at 2, 4, or 6 hours 
post-dose. Bronchoscopy was performed as previously described [23], with lavage of the 
right middle lobe. A cell count was obtained by haemocytometry, before centrifugation to 
obtain samples of cell pellet and supernatant. The volume of epithelial lining fluid in 
bronchoalveolar lavage was calculated using the urea dilution method [13,17–20]. 
 
Rifampicin, isoniazid, pyrazinamide and ethambutol concentrations were measured in 
plasma, bronchoalveolar lavage supernatant, and cell pellets with a four-drug liquid 
chromatography / tandem mass spectrometry assay using appropriate internal standards 
validated to internationally recognized acceptance criteria (Supplementary Materials). 
 
Pharmacokinetic modelling 
Population pharmacokinetic models were developed using NONMEM© (version 7.4.0, ICON 
Development Solutions). A two-stage model-building strategy was used: first the plasma-
only pharmacokinetic models were developed for each drug, then the plasma and 
intrapulmonary pharmacokine ic data were analysed under a combined model 
(Supplementary Materials).  
 
One- and two-compartment pharmacokinetic disposition models with alternative models of 
absorption were explored in fittings to the plasma data. Base model selection was achieved 
using likelihood ratio testing with the minimum objective function value as the criterion, and 
examination of relative standard error values and goodness-of-fit plots. Stepwise 
generalised additive modelling was then used to identify significant covariates for the model 
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(from among age, weight, body mass index, sex, HIV status, and creatinine clearance). The 
plasma models were evaluated using visual predictive checks.  
 
Concentrations in the epithelial lining fluid and alveolar cell compartments were 
characterised by ratio parameters relative to their plasma concentration (RELF and RAC 
respectively). Interindividual variability on RELF and RAC was incorporated using an 
exponential error model with separate residual error variances estimated for both epithelial 
lining fluid and alveolar cells. RELF is based on total drug (protein-unbound plus bound), 
whereas only the unbound fraction is pharmacologically-active and able to be transported 
or diffuse into the epithelial lining fluid [27]. Of the four first-line drugs, only rifampicin has 
extensive protein binding. Assuming an unbound fraction of rifampicin in plasma of 20%  
[27], and negligible protein binding in epithelial lining fluid [28], we approximated the 
RELF/unbound-plasma ratio to be five-fold greater than RELF/total-plasma. 
 
Model-based estimates of individual values of AUC, Tmax, and Cmax were calculated from 
empirical Bayes estimates of parameters (Supplementary Materials). Plasma Cmax estimates 
were compared to therapeutic drug monitoring targets: rifampicin ≥ 8 μg/ml, isoniazid ≥ 3 
μg/ml, pyrazinamide ≥ 20 μg/ml, and ethambutol ≥ 2 μg/ml [29]. Rifampicin AUC > 13 
μg.h/ml, isoniazid AUC > 52 μg.h/ml, pyrazinamide Cmax > 35 μg/ml and AUC > 363 μg.h/ml 
were also considered given associations with improved outcomes in one analysis [7,30]. 
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Treatment response and bacteriology 
Sputum samples were collected at treatment initiation, 2-months, and at end-of-treatment. 
Baseline drug susceptibility of screening isolates was measured on custom-made microtitre 
plates (UKMYC3 Sensititre, Thermo Scientific). These assays used 96-well plates with 
increasing concentrations of rifampicin (0.015-16 µg/ml), isoniazid (0.015-16 µg/ml), and 
ethambutol (0.25-16 µg/ml) (Supplementary Materials). 
 
Two-month culture conversion in liquid media was captured. Participants with negative TB 
sputum cultures from end-of-treatment onwards or who stopped coughing and remained 
well after treatment were defined as having a favourable clinical outcome. Recurrent TB 
(relapse/re-infection), failed treatment, and death were grouped together as unfavourable 
clinical outcomes. Logistic regression, chi-squared test, and Fisher’s exact test were used to 
assess relationships between pharmacokinetics and treatment response.  
 
Ethics 
Ethical approval was obtained from the Research Ethics Committees of the College of 
Medicine, University of Malawi, and the Liverpool School of Tropical Medicine.  
Results 
Demographic and clinical description of cohort 
We recruited 157 adult patients with pulmonary TB (Table 1).  Median age was 34 years 
(IQR: 28-39), 76.4% were male (120/157), and 58.0% had HIV co-infection (91/157). More 
than half of co-infected participants (57.1%, 52/91) were diagnosed with HIV during TB 
diagnosis.  
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Use of fixed-dose combination regimens resulted in administration of a median rifampicin 
dose of 9.4 mg/kg (IQR 8.8-10.3), isoniazid 4.7 mg/kg (IQR 4.4-5.1), pyrazinamide 25.2 
mg/kg (IQR 23.5-27.4), and ethambutol 17.3 mg/kg (IQR 16.2-18.8). Four (2.5%) participants 
were under-dosed for rifampicin and isoniazid, and 5 (3.2%) for ethambutol according to the 
WHO recommended range (rifampicin 10 mg/kg, isoniazid 5 mg/kg, pyrazinamide 25 mg/kg, 
ethambutol 15 mg/kg)[31]. No correlation was seen between the radiological extent of right 
midzone disease and intrapulmonary drug concentration (Supplementary Figure 1). 
 
Rifampicin pharmacokinetics 
The rifampicin dataset comprised 741 plasma concentration-time observations from 140 
participants. The plasma data were best described by a one-compartment disposition model 
with first-order absorption and elimination. Only sex and HIV status were identified as 
significant covariates: the final model showed 32% greater clearance in male participants 
(CL/F; 16.1 L/h male versus 12.2 L/h female), and 34% greater volume of distribution in HIV-
infected participants (V/F; 29.7 L HIV-infected versus 22.2 L HIV-uninfected). The visual 
predictive check and goodness-of-fit plots indicated that the final plasma model performed 
adequately (Supplementary Figures 2 and 3).  
 
Rifampicin concentrations in epithelial lining fluid and alveolar cells exceeded those in 
plasma. Eighty-three sparse concentration-time observations in epithelial lining fluid and 89 
in alveolar cells, from 51 participants, were included in the final combined intrapulmonary 
model. The final model parameters are included in Supplementary Table 1. The extent of 
distribution to epithelial lining fluid was near double that of plasma with typical predicted 
RELF of 1.97 (95% CI: 1.65-2.30) and was elevated for alveolar cells also (RAC 1.35 [95% CI: 
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0.89-1.81]). After accounting for plasma protein binding, the RELF/unbound-plasma ratio will be 
approximately five-fold greater than the RELF/total-plasma recorded here: 9.85 compared to 
1.97.  
 
Rifampicin drug exposure in plasma was low relative to therapeutic drug monitoring targets 
(Cmax 4.0 μg/ml [3.5-4.8] for total drug, target ≥ 8 μg/ml [29]; Figure 1 and Table 2). 
Rifampicin drug exposure was greatest in the epithelial lining fluid compared to plasma and 
alveolar cells. 
 
Isoniazid pharmacokinetics  
The isoniazid plasma dataset contained 750 concentration-time observations from 140 
participants, best described by a one-compartment pharmacokinetic model with first-order 
absorption and elimination. Two-compartment models were met with some improvement 
in the objective function value, but unacceptably poor precision of parameter estimates. 
Weight as an effect on volume of distribution (V/F) was the only covariate that significantly 
improved the model fit, with the volume of distribution increasing by 1.08 L for every kg 
above the population mean of 51.1 kg.  
 
Eighty-eight epithelial lining fluid and 89 alveolar cell concentration-time observations from 
51 participants were available for the second stage of modelling. Isoniazid distributed 
extensively to epithelial lining fluid, with concentrations nearly 15-fold greater than plasma 
(RELF 14.6 [95% CI: 11.2-18.0], Supplementary Table 1). Concentrations in alveolar cells were 
closer to plasma (RAC 1.31 [95% CI: 0.95-1.67]). The high concentrations achieved in 
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epithelial lining fluid are demonstrated on the summary concentration-time plot (Figure 1) 
and estimates in Table 2.  
 
Pyrazinamide pharmacokinetics 
Four-hundred-and-nine observations from 131 participants were modelled. Inclusion of 
weight as a covariate for both clearance (CL/F) and volume of distribution (V/F) significantly 
improved the model fit.  
 
Fifty concentration-time observations were available for intrapulmonary pharmacokinetic 
modelling  (Supplementary Table 1). Pyrazinamide was extensively distributed to epithelial 
lining fluid, achieving a RELF of 49.8 (95% CI: 34.2-65.3). Median pyrazinamide Cmax in 
epithelial lining fluid was 1,195 μg/ml (IQR 1,062-1,361), as compared to 24.0 μg/ml (IQR 
22.2-26.3) in plasma (Table 2). Pyrazinamide was observed to accumulate in alveolar cells, 
with concentrations 3.18-fold greater than plasma (95% CI: 1.90-4.46). No patients achieved 
the proposed Cmax target of > 35 μg/ml, while only 37 (23.1%) patients achieved an AUC > 
363 μg.h/ml. 
 
Ethambutol pharmacokinetics 
Four-hundred-and-sixteen ethambutol plasma concentration-time observations were 
modelled. Again, a one-compartment disposition model with first-order absorption was 
sufficient to describe the data and attempts to use a two-compartment system or 
incorporate an absorption lag phase were met with non-convergence. After stepwise 
backwards elimination, only creatinine clearance as an effect on clearance (CL/F) was 
retained as a covariate in the model.  
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Fifty epithelial lining fluid and alveolar cell concentration-time observations for ethambutol 
were available. Final parameter estimates from the final intrapulmonary pharmacokinetic 
model show that in contrast to the other 3 first-line drugs, highest ethambutol levels were 
seen in the alveolar cells (RAC 15.0 [95% CI: 11.4-18.6], Supplementary Table 1 and Figure 1), 
while concentrations in epithelial lining fluid were 4-fold higher than plasma (95% CI: 3.3-
4.6). While median plasma Cmax was low at 1.3 μg/ml (IQR 1.1-1.6), higher peak 
concentrations of 5.2 μg/ml (IQR 4.2-6.6) and 20.0 μg/ml (15.4-25.3) were seen in epithelial 
lining fluid and alveolar cells respectively.   
 
Drug susceptibility 
Baseline isolates (n=88) were highly sensitive to rifampicin: the modal minimum inhibitory 
concentration (MIC) was 0.015, 0.03, and 0.5 μg/ml for rifampicin, isoniazid, and 
ethambutol respectively (Figure 2). One-hundred-thousand AUC, Cmax, and MIC values were 
generated from the mean and standard deviation using Monte Carlo simulation, and used to 
describe the likely distribution of AUC/MIC and Cmax/MIC in this cohort (Table 3). 
 
Relationship with clinical outcome 
One-hundred-and-twenty-six participants had sufficient data to assess 2-month culture 
conversion: 81 (64%) had stable culture conversion by 2-months. Clinical outcome was 
captured in 133 participants, with 15 (11%) unfavourable outcomes recorded. Two-month 
culture conversion was not predictive of clinical outcome (p<0.05; McNemar’s hypothesis 
test for paired data). We observed no relationship between rifampicin AUC > 13 μg.h/ml, 
isoniazid AUC > 52 μg.h/ml, or pyrazinamide AUC > 363 μg.h/ml and clinical outcome 
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(p=1.000, Fisher’s exact test), nor any association between baseline MIC and 2-month 
culture conversion or final outcome by logistic regression. None of the plasma or 
intrapulmonary pharmacokinetic parameters were associated with culture conversion or 
late clinical outcome (Table 4).  
Discussion 
We observed low plasma drug concentrations for all four first-line anti-TB drugs in Malawian 
adults, relative to established therapeutic drug monitoring targets [29]. In addition, we 
report differences in drug concentrations between plasma and pulmonary compartments. 
Rifampicin concentrations were low in both compartments, suggesting that the current 
recommended dose is not optimal. While plasma concentrations of isoniazid, pyrazinamide 
and ethambutol were also low, these drugs achieved higher concentrations in epithelial 
lining fluid and alveolar cells; accumulation at the tissue site of disease may be important for 
the success of first-line anti-TB therapy.  
 
The observed low plasma drug concentrations were consistent with other studies of steady-
state pharmacokinetics from TB patients in high-endemicity settings [2,32–35]. Target 
concentrations for therapeutic drug monitoring were derived from descriptions of drug 
exposure in both patients and healthy volunteers, and have been associated with clinical 
outcomes in some studies [10,29]. Furthermore, most patients in our study did not achieve 
the proposed Cmax (pyrazinamide: 35 μg/ml) or AUC cut-offs (isoniazid: 52 μg.h/ml; 
pyrazinamide: 363 μg.h/ml) identified as predictive of long-term response [7]. Taken 
together, we suggest that current dosing might be too low to achieve pharmacokinetic 
targets. 
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All four drugs achieved higher concentrations in epithelial lining fluid and alveolar cells than 
plasma, with isoniazid and pyrazinamide 15- and 50-fold higher in lining fluid than plasma 
respectively, and ethambutol concentrating within the cells. Our findings differ from 
previous work, where rifampicin epithelial lining fluid concentrations were reported to be 
one-fifth of plasma concentrations [17], and less extensive distribution of isoniazid and 
pyrazinamide to lining fluid was observed [18,19]. Whereas previous work occurred in 
healthy volunteers (with or without HIV infection), the samples in the present study came 
from a cohort of adult patients with active pulmonary TB, many of whom were significantly 
immunosuppressed. Active inflammation, with increased permeability, cellular influx, and 
disruption of the blood-alveolar barrier may alter tissue drug penetration in those with 
ongoing infection [27]. Peak intrapulmonary concentrations were seen 2 hours after drug 
administration, suggesting that single pharmacokinetic measurements at 4 hours in previous 
studies underestimated drug exposure. 
 
Despite low plasma drug concentrations, 89% of our cohort had a favourable clinical 
outcome. AUC/MIC and Cmax/MIC for first-line drugs have been described as drivers of 
treatment efficacy in pre-clinical models [36–39], but local variation in MICs of non-
genotypically resistant Mycobacterium tuberculosis isolates against first-line TB drugs have 
not been well described. High plasma and intrapulmonary AUC/MIC and Cmax/MIC ratios 
[8,38] were achieved in this cohort as a result of steady-state accumulation of drugs at the 
site of disease, coupled with preserved drug sensitivity, particularly for rifampicin. 
 
Dose optimisation may yield further improvements in treatment outcomes. Only two-thirds 
(64%) of the patients had culture converted by 2-months, despite drug-sensitive disease, 
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good adherence, and intensive follow-up. We postulate that the slow bacillary clearance 
and unfavourable clinical outcomes are a consequence of the observed plasma and 
intrapulmonary rifampicin exposure. Rifampicin dosing studies have demonstrated that 
increased dosing may be associated with supra-proportional increases in plasma AUC [40] 
and improved early bactericidal activity [41]. These studies have typically used mg/kg doses 
several fold greater than used in the present study, which may markedly increase rifampicin 
exposure within the intrapulmonary compartment. HIV-infected participants were observed 
to have a greater volume of distribution for rifampicin, likely reflecting reduced 
bioavailability in co-infected patients [42].    
 
We were unable to detect a relationship between plasma or intrapulmonary 
pharmacokinetics and treatment response in this cohort using standard approaches. 
Exploratory methods such as those based on machine learning might offer further insights 
into these relationships and may form the basis of future work. Given a relatively narrow 
exposure across a constant mg/kg range using weight-banded dosing, studies assessing a 
greater range of dosing may be required to fully delineate relationships between 
pharmacokinetics and binary clinical outcomes. Alternatively, modelled bacillary elimination 
rates, as a continuous measure of treatment response, may identify pharmacokinetic-
pharmacodynamic relationships from studies of fewer participants [41,43]. Even if dose 
refinement is not associated with improved rates of relapse-free cure, identification of 
factors associated with more rapid bacillary elimination may be important for interruption 
of transmission and reduction of post-TB lung disease. 
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There were several limitations to our study. Bronchoalveolar lavage may result in drug efflux 
from macrophages, but these effects were minimised by placing samples on ice, and rapid 
centrifugation. The cell pellet obtained from bronchoalveolar lavage contains a mixture of 
alveolar macrophages, epithelial cells, lymphocytes and other leukocytes, and the drug 
concentration is recorded in μg/ml of cells.  Alveolar macrophages represent more than 80% 
of cells in lavage, and are the largest cells retrieved [23], and as such, the alveolar cell 
concentrations are more likely to be an underestimation of macrophage drug concentration. 
Finally, we were only able to measure MICs from a subset of baseline isolates, nstead using 
summary estimates to describe AUC/MIC and Cmax/MIC distributions for the cohort.  
 
These are the only data describing the steady-state intrapulmonary pharmacokinetics of 
first-line anti-TB therapy in patients with pulmonary disease. Ultimately, understanding the 
mismatch in antibiotic exposure between plasma and site of infection may aid dose 
refinement and development of optimal pan-TB regimens for both drug-sensitive and drug-
resistant disease. 
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Figure Legends 
Figure 1: Concentration-time plots for rifampicin, isoniazid, pyrazinamide and ethambutol 
in plasma, epithelial lining fluid, and alveolar cells 
Summary concentration-time plots for rifampicin, isoniazid, pyrazinamide, and ethambutol 
in plasma, epithelial lining fluid, and alveolar cells from population means at steady state. To 
account for rifampicin protein-binding, the red/pink shaded area in the top-left panel 
illustrates plasma drug exposure for total drug (top line) or unbound drug (bottom line), 
assuming 80% protein-binding in plasma and negligible protein-binding in epithelial lining 
fluid. Plasma concentrations for isoniazid, pyrazinamide, and ethambutol shown as total 
drug only. Concentrations at the different timepoints were calculated using the Bayesian 
posterior pharmacokinetic parameter value estimates, and epithelial lining fluid:plasma 
(RELF) and alveolar cells:plasma (RAC) ratios. The horizontal dotted line represents the plasma 
targets for therapeutic drug monitoring [29]. 
 
Figure 2: Baseline drug sensitivity 
Drug sensitivity in baseline sputum Mycobacterium tuberculosis isolates determined using 
microtitre plates (n=88). Pyrazinamide was not assessed due to its’ need for acidic test 
conditions. The minimum inhibitory concentration (MIC) was recorded as the lowest 
concentration in the microtitre plate with no visible growth observed. The currently 
recommended critical concentration (breakpoint) is indicated by the dashed line [44]. 
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Table 1: Demographic and clinical description of cohort 
Characteristic Total  
(n=157) 
Intrapulmonary arm 
(n=51) 
Plasma arm  
(n=106) 
Age (years), median [IQR] 34 [28-39] 32 [26-36] 34 [28-41] 
Male sex, n (%) 120 (76.4) 44 (86.3) 76 (71.7) 
Weight (kg), median [IQR] 51.1 [46.9-55.6] 50.0 [47.3-53.8] 52.0 [46.6-56.5] 
Body mass index (kg/m2), median [IQR] 18.4 [17.0-19.8] 17.9 [16.8-18.9] 18.7 [17.1-20.1] 
HIV-infected, n (%) 91 (58.0) 23 (45.1) 68 (64.2) 
Baseline CD4 count in HIV-infected patients (cells/mm3), median [IQR] 
(n=91) 
178 [80-285] 178 [93-273] 175 [77-284] 
On antiretroviral therapy at baseline if HIV-infected, n (%) 39 (42.9) 10 (43.5) 29 (42.6) 
Rifampicin/isoniazid/pyrazinamide/ethambutol dose (mg), n (%) 
300/150/800/550 
450/225/1200/825 
600/300/1600/1100 
 
3 (1.9) 
107 (68.2) 
45 (28.7) 
 
1 (2.0) 
38 (74.5) 
12 (23.5) 
 
2 (1.9) 
69 (65.1) 
33 (31.1) 
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750/375/2000/1375 2 (1.3) 0 (0.0) 2 (1.9) 
Adherence, n (%) a 
    Missed no doses 
    Missed 1-2 doses 
    Missed >2 doses 
 
135 (86.0) 
14 (8.9) 
8 (5.1) 
 
41 (80.4) 
6 (11.8) 
4 (7.8) 
 
94 (88.7) 
8 (7.5) 
4 (3.8) 
 
IQR: interquartile range  
a Adherence assessed by direct questioning and pill counts 
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Table 2: Final steady state parameter estimates for drug exposure (AUC and Cmax) in plasma, epithelial lining fluid, and alveolar cells 
Drug Pharmaco-kinetic 
index 
Plasma 
therapeutic drug 
monitoring target 
[29] 
Matrix 
Plasma 
(median [IQR]) 
Epithelial lining fluid 
(median [IQR]) 
Alveolar cells (median 
[IQR]) 
Rifampicin AUC (μg.h/ml) 
AUC (μg.h/ml) 
Cmax (μg/ml) 
Cmax (μg/ml) 
- 
- 
- 
≥ 8 μg/ml 
6.6 [5.6-7.5] a 
30.6 [27.3-36.7] b 
0.8 [0.3-1.0] a  
4.0 [3.5-4.8] b 
65.7 [52.4-77.1] 
 
7.8 [6.4-10.0] 
46.0 [36.4-55.1] 
 
5.3 [4.4-7.6] 
Isoniazid AUC (μg.h/ml) 
Cmax (μg/ml) 
- 
≥ 3 μg/ml 
19.0 [11.9-25.9] 
2.6 [2.4-3.0] 
277.8 [154.9-382.4] 
38.9 [32.8-46.2] 
24.4 [14.1-34.8] 
3.5 [2.9-4.2] 
Pyrazinamide AUC (μg.h/ml) 
Cmax (μg/ml) 
- 
≥ 20 μg/ml c 
319.5 [292.0-384.3] 
24.0 [22.2-26.3] 
16,062 [14,096-19,403] 
1,195 [1,062-1,361] 
1,036 [899-1,272] 
78 [68-94] 
Ethambutol AUC (μg.h/ml) 
Cmax (μg/ml) 
- 
≥ 2 μg/ml 
5.4 [2.9-7.4] 
1.3 [1.1-1.6] 
22.6 [11.7-29.2] 
5.2 [4.2-6.6] 
83.0 [48.0-110.1] 
20.0 [15.4-25.3] 
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AUC: area under the concentration-time curve; Cmax: peak concentration; IQR: interquartile range 
a Estimated unbound fraction of rifampicin in plasma, assuming typical 80% rifampicin protein binding   
b Total rifampicin in plasma 
c Pyrazinamide Cmax ≥ 35 μg/ml has also been proposed as a target due to association with improved outcomes [30] 
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Table 3: Summary of pharmacokinetic indices from modelled plasma data 
Drug Simulated plasma median 
AUC/MIC [IQR] 
Simulated plasma median 
Cmax/MIC [IQR] 
Rifampicin a 2,319 [1422-3786] 285.0 [178.3-456.2] 
Isoniazid 448 [438-458] 75.4 [66.7-85.3] 
Pyrazinamide b - - 
Ethambutol 64 [17-239] 4.0 [1.1-14.6] 
 
Minimum inhibitory concentration (MIC) data available from baseline isolates from 88 
participants. Using the mean and standard deviation for AUC, Cmax, and MIC from this 
dataset, 100,000 AUC/MIC and Cmax/MIC pairings generated using Monte Carlo simulation to 
estimate the data distribution.   
a Rifampicin AUC and Cmax based on total (protein bound + unbound) drug 
b MIC data not available for pyrazinamide 
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Table 4: Pharmacokinetic indices and treatment response 
Pharmacokinetic parameter Odds ratio for 2-
month culture 
conversion  
(95% CI) 
P value Odds ratio for 
favourable outcome 
(95% CI) 
P value 
Drug Matrix Pharmacokinetic index 
Rifampicin Plasma AUC (μg.h/ml) 1.01 (0.95-1.07) 0.815 1.03 (0.95-1.14) 0.488 
Cmax (μg/ml) 1.02 (0.73-1.44) 0.918 1.68 (0.91-3.47) 0.125 
Epithelial lining 
fluid a 
AUC (μg.h/ml) 1.02 (1.00-1.04) 0.118 1.09 (0.99-1.43) 0.321 
Cmax (μg/ml) 1.17 (1.01-1.45) 0.085 2.03 (0.97-9.24) 0.221 
Alveolar cells a AUC (μg.h/ml) 1.00 (0.99-1.02) 0.607 1.00 (0.99-1.05) 0.836 
Cmax (μg/ml) 1.05 (0.93-1.19) 0.429 1.03 (0.89-1.43) 0.801 
Isoniazid Plasma AUC (μg.h/ml) 0.98 (0.94-1.02) 0.281 1.07 (0.99-1.18) 0.100 
Cmax (μg/ml) 1.24 (0.58-2.68) 0.583 3.79 (0.96-17.86) 0.071 
Epithelial lining 
fluid a 
AUC (μg.h/ml) 1.00 (1.00-1.00) 0.372 1.00 (1.00-1.01) 0.575 
Cmax (μg/ml) 1.02 (1.00-1.04) 0.116 1.03 (0.98-1.15) 0.400 
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Alveolar cells a AUC (μg.h/ml) 1.00 (0.98-1.02) 0.992 1.00 (0.98-1.06) 0.980 
Cmax (μg/ml) 1.04 (0.85-1.30) 0.674 1.01 (0.73-1.77) 0.959 
Pyrazinamide Plasma AUC (μg.h/ml) 1.00 (0.99-1.00) 0.303 1.00 (1.00-1.01) 0.751 
Cmax (μg/ml) 1.01 (0.91-1.13) 0.869 1.07 (0.90-1.29) 0.464 
Epithelial lining 
fluid a 
AUC (μg.h/ml) 1.00 (1.00-1.00) 0.652 1.00 (1.00-1.00) 0.356 
Cmax (μg/ml) 1.00 (1.00-1.00) 0.217 1.00 (1.00-1.01) 0.341 
Alveolar cells a AUC (μg.h/ml) 1.00 (1.00-1.00) 0.276 1.00 (1.00-1.00) 0.443 
Cmax (μg/ml) 1.00 (0.99-1.01) 0.483 1.01 (0.99-1.06) 0.489 
Ethambutol Plasma AUC (μg.h/ml) 1.08 (0.92-1.27) 0.360 0.91 (0.71-1.17) 0.465 
Cmax (μg/ml) 0.85 (0.32-2.29) 0.743 1.12 (0.25-5.86) 0.889 
Epithelial lining 
fluid a 
AUC (μg.h/ml) 0.97 (0.82-1.12) 0.658 1.06 (0.89-1.73) 0.733 
Cmax (μg/ml) 0.98 (0.70-1.35) 0.878 1.05 (0.71-2.32) 0.856 
Alveolar cells a AUC (μg.h/ml) 0.99 (0.95-1.02) 0.469 1.07 (0.97-1.28) 0.345 
Cmax (μg/ml) 0.98 (0.91-1.05) 0.584 1.11 (0.92-1.55) 0.420 
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AUC: area under the concentration-time curve; Cmax: peak concentration 
a Analysis restricted to those in the intrapulmonary group 
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